News Stroke data breathes life back into Bayer's asundexian Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
News J&J abandons Alzheimer's antibody in setback for tau Hopes that anti-tau drugs could emerge as treatments for Alzheimer's have been dented by the failure of a phase 2b trial of J&J's posdinemab.
News J&J swoops on cancer biotech Halda with $3bn takeover deal Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy Halda Therapeutics and its RIPTAC anticancer platform.
News BMS, J&J give up on milvexian for acute coronary syndrome BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.
News J&J adds first new indication for Caplyta since takeover Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.
News "Significant shift" as NICE widens prostate cancer drug use NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.